Q3 2021 Investor Relations Results slide image

Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Cardiovascular, Renal and Metabolic 60 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine
View entire presentation